L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.

@article{Mehta2012LBLP25VP,
  title={L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.},
  author={Neelima Rakesh Mehta and Gregory T. Wurz and Rebekah A. Burich and Brittany E. Greenberg and Stephen M. Griffey and Audrey M Gutierrez and Katie E. Bell and Jamie L McCall and M Wolf and Michael Degregorio},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 10},
  pages={2861-71}
}
PURPOSE In this study, we examine the immunomodulatory effects and antitumor activity of tamoxifen and letrozole when combined with the human epithelial mucin (hMUC1)-specific vaccine, L-BLP25, in the hMUC1-expressing mammary tumor (MMT) mouse model. EXPERIMENTAL DESIGN Dose-finding studies were conducted for both tamoxifen and letrozole. Letrozole and L-BLP25 combination studies used 69 MMT female mice assigned to five groups: untreated, cyclophosphamide + placebo, cyclophosphamide + L-BLP25… CONTINUE READING